The new wound care division and the subsequent agreement with Pharmaplast spotlights MediPurpose’s attention on new business development to expand medical product lines that complement their medical product distribution services and logistics capabilities.

Pharmaplast said that the agreement enables the company access to an expanded market for its products within the Americas while continuing to expand their worldwide presence.

Randy Prather, COO and president of MediPurposewho oversees the Wound Care division, said: “Pharmaplast’s quality and breadth of product line of advanced wound care products is the ideal foundation for our Wound Care division.”

“Our distribution services capability was a key advantage that MediPurpose was able to offer that cemented the relationship with our new OEM partner. MediPurpose’s goal was to provide a quality, comprehensive advanced wound care line that would afford substantial profit opportunities for our existing and new distribution partners who service this market. Pharmaplast provided us the opportunity to meet and exceed those original goals.

“Additionally, with the launch of this new division, we are very excited about the opportunities to expand the division’s product capabilities by partnering with additional wound care products manufacturers that offer complementary products in the Americas and abroad.”

Patrick Yi, founder and CEO of MediPurpose, said: “It is our responsibility to ensure that all our new medical product lines achieve the same superior product quality and customer service as our current SurgiLance safety lancet product line. After an exhaustive evaluation, I am confident that our customers will receive the same standard of service from Pharmaplast.”